Allarity Therapeutics, Inc. (NASDAQ: ALLR) closed a $20 million non‑convertible debt financing with Streeterville Capital on March 6 2026. The transaction consists of a $10.93 million unsecured promissory note and a $10 million secured promissory note, providing the company with net proceeds of approximately $20 million.
The proceeds are earmarked to extend Allarity’s cash runway into the summer of 2028 and to fund key milestones, including the completion of Phase 2 enrollment for its lead asset stenoparib, preparation for an upcoming FDA meeting, and advancement of its Drug Response Predictor (DRP) companion diagnostic platform. The company also plans to use the funds for exploratory development in additional WNT‑driven tumor types.
Allarity’s current cash balance is about $16.9 million, a figure that, while not directly verified for March 6, aligns with the company’s historical burn rate and supports operations through mid‑2028. The financing is non‑convertible, allowing the company to avoid immediate equity dilution, but it carries restrictive covenants that limit future financings, subsidiary activities, and impose potential default remedies. The company remains pre‑revenue and has faced prior regulatory scrutiny, including a Wells Notice in July 2024 and a civil penalty settlement in March 2025, underscoring the importance of maintaining liquidity.
CEO Thomas Jensen said, "This financing demonstrates the confidence which Streeterville has in Allarity and the capital received positions us to complete Phase 2 enrollment, prepare for our FDA meeting, advance our companion diagnostic strategy, and prepare for pivotal development of stenoparib in advanced ovarian cancer." The quote highlights the strategic intent behind the funding and the company’s focus on advancing its flagship therapy.
Stenoparib is a dual PARP and WNT pathway inhibitor that has received FDA Fast Track designation for advanced ovarian cancer. Allarity is also conducting a Phase 2 trial for relapsed small cell lung cancer in collaboration with the U.S. Department of Veterans Affairs, illustrating the broader therapeutic potential of its platform.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.